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ABSTRACT
The human arylamine N-acetyltransferase 1 (NAT1) is critical in determining the duration of action and
pharmacokinetics of amine-containing drugs such as para-aminosalicylic acid and para-aminobenzoyl
glutamate used in clinical therapy of tuberculosis (TB), as well as influencing the balance between detox-
ification and metabolic activation of these drugs. SNPs in this enzyme are continuously being detected
and indicate inter-ethnic and inter-individual variation in the enzyme function. The effect of nsSNPs on
the structure and function of proteins are routinely analyzed using SIFT and POLYPHEN-2 prediction
algorithms. The false-negative rate of these two algorithms results in as much as 25% of nsSNPs. This
study aimed to explore the use of homology modeling including residue interactions, Gibbs free energy
change and solvent accessibility as additional evidence for predicting nsSNP effects on enzyme function.
This study evaluated the functional effects of 14 nsSNPs identified in a South African mixed ancestry
population of which 3 nsSNPs were previously identified in Caucasians. The SNPs were evaluated using
structural analysis that included homology modeling, residue interactions, relative solvent accessibility,
Gibbs free energy change and sequence conservation in addition to the routinely used nsSNP function pre-
diction algorithms, SIFT and POLYPHEN-2. The structural analysis implemented in this study showed
a loss of hydrogen bonds for S259R thereby affecting protein function which contradicts predictions
obtained from SIFT and POLYPHEN-2 algorithms. The variant N245I was shown to be neutral but con-
tradicted the predictions from SIFT and POLYPHEN-2. Structural analysis predicted that variant R242M
would affect protein stability and therefore NAT1 function in agreement with POLYPHEN-2 predictions
but contradicting predictions from SIFT. No structural changes were expected for variant E264K in agree-
ment with predictions obtained from POLYPHEN-2 but contradicting results from SIFT. The functions
of the remaining 10 nsSNPs were consistent with those predicted by SIFT and POLYPHEN-2 namely
xi
 
 
 
 
that four variants R117T, E167Q, T193S and T240S do not affect the NAT1 function whereas R166T,
F202V, Q210P, D229H, V231G and V235A could affect the enzyme function.
This study provided the first evaluation of the functional effects of 11 newly characterized nsSNPs on
the NAT1 tuberculosis drug-metabolizing enzyme. The six functionally important nsSNPs predicted by
all three methods and the four SNPs with contradictory results will be tested experimentally by creat-
ing a SNP construct that will be cloned into an expression vector. These combined computational and
experimental studies will advance our understanding of NAT1 structure-function relationships and allow
us to interpret the NAT1 genetic polymorphisms in individuals who are slow or fast acetylators. The
results, albeit a small dataset demonstrate that the routinely used algorithms are not without flaws and
that improvements in functional prediction of nsSNPs can be obtained by close scrutiny of the molecular
interactions of wild type and variant amino acids.
xii
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Chapter 1
INTRODUCTION AND LITERATURE REVIEW:
1.1 Arylamine N-acetyltransferases (NATs)
Arylamine N-acetyltransferases (NATs) are xenobiotic metabolizing enzymes (XMEs) that affect the bi-
ological activity and toxicity of compounds, including tuberculosis (TB) drugs. These enzymes are found
in both prokaryotes and eukaryotes [1]. NATs catalyze either the acetyl-CoA dependent N-acetylation
of primary aromatic amines and hydrazines (usually deactivating the drug) or the O-acetylation of their
N-hydroxylated metabolites (usually activating the drug). Specifically, NATs transfer acetyl group from
acetyl-CoA to the nitrogen or oxygen atom of primary aromatic amines, hydrazines and N-hydroxylated
metabolites of such compounds [2]. Therefore, NATs play a vital role in detoxification and potential
metabolic activation of numerous xenobiotic substances.
Human NAT1 and NAT2, (33kD and 31kD proteins respectively) are products of protein-coding exons of
870-bp open reading frames encoding 290 amino acids [3, 4, 5, 6]. So far NAT genes have been identified
in 1674 prokaryotic and 464 eukaryotic genomes [1] and encode between 254 and 332 amino acids [7].
These genes together with a pseudogene, NATP, are located on human chromosome 8p22 [3, 8]. The NAT
loci are separated by 170-360kb and are positioned NAT1 to NATP to NAT2, where NAT1 is located on
the centromeric side of marker D8S261 and NAT2 near marker D8S21 [9]. An 87% nucleotide sequence
identity is shared in the coding region between NAT1 and NAT2 or an 81% identity at the amino acid level
resulting in 55 amino acid differences. The open reading frames of both enzymes are shown in Figure
1
 
 
 
 
1.1.
Figure 1.1 Protein coding exons of human NAT1 and NAT2
ORF- Open reading frame.
NAT1 protein is encoded by a single exon (9) whereas NAT2 mRNA is obtained from both the protein-coding exon (2) and a
second non-coding exon of 100-bp located about 8 kb upstream of the translation start site (1) [3, 10]
A multiple sequence alignment of NAT proteins indicates that most conserved regions occur at the amino
terminus, whereas the carboxyl terminus displays little conservation between the species [7]. All NATs
possess the conserved C68/C69, H107 and D122 residues suggested to form a catalytic triad (Figure 1.2).
Inhibitor [11, 12] and site-directed mutagenesis studies [13] confirm that the C68 in human proteins is
crucial for NAT activity. In humans, the two functional NATs, NAT1 and NAT2, are both expressed
in liver [14] while only NAT1 is expressed in mononuclear leukocytes [15]. Human NAT1 catalyses the
metabolism of para-aminosalicylic acid [16] used in the treatment of tuberculosis; one of the most serious
2
 
 
 
 
lung diseases in the world.
Figure 1.2 NAT1 active site
Catalytic triad residues C68, H107 and D122 are highlighted in pink.
1.2 Tuberculosis
According to the 2010 World Health Organization (WHO) Report [17], in 2009 there were an estimated
9.4 million incident cases of TB globally, implying 137 cases per 100000 humans. Most incidents were
recorded in the South-East Asia, Africa and the Western Pacific (Figure 1.3).
With approximately 0.5 million cases, South Africa is among the five countries with the largest number
of incidents. Here, the problem of TB is complicated by HIV/TB co-infections. HIV increases the
susceptibility of a patient to infection with tuberculosis and the spread of HIV epidemic in the past decade
has been accompanied by up to a fourfold increase in the number of TB cases [18]. It is estimated that up
to 50% of new adult cases of TB in South Africa are co-infected with HIV [19]. These statistics indicate
that tuberculosis remains a serious health problem affecting the world with devastating economic, social
and financial burdens calling for effective measures to identify, prevent, control and treat tuberculosis.
3
 
 
 
 
Figure 1.3 Estimated incidence of all forms of TB, classified by WHO Regions, 2009
Source: Global Tuberculosis Control; WHO Report 2010, World Health Organisation, Geneva 2010. WHO/HTM/2010.7
The treatment of TB falls into two phases: an initial intensive phase and a continuation phase or consol-
idation phase. WHO recommends an intensive phase of two months with isoniazid, rifampicin, pyraz-
inamide and ethambutol for all new cases and a continuation phase of four months with isoniazid and
rifampicin [17]. In combination with streptomycin these drugs form what is known as the first-line drugs
for TB treatment. A drug may be classified as second-line instead of first-line for various reasons, namely
it is less effective than the first-line drug (e.g para-aminosalicylic acid (p-AS)), it has toxic side-effects
(e.g. cycloserine) or is unavailable in many developing countries (e.g. fluoroquinolones). Second line
drugs include kanamycin, viomycin, ciprofloxacin, prothiomide, p-AS and a host of others. Until 2007,
the standard treatment regimen in South Africa consisted of a four-month intensive phase with five anti-
TB drugs (kanamycin, ethionamide, pyrazinamide, ofloxacin and cycloserine or ethambutol), followed
by a 12-18 months continuation phase with three drugs (ethionamide, ofloxacin and cycloserine or etham-
butol) [20]. These drugs were administered five times per week in out-patient clinics and seven times per
week in hospitals.
However, an increasing number of TB infections have become resistant to the major anti-tuberculosis
drugs [21, 22, 23]. Two types of drug resistance can be identified: multi-drug resistant TB (MDR-TB)
and extensively drug resistant TB (XDR-TB). Multi-drug resistant TB is a form of tuberculosis that
4
 
 
 
 
fails to respond to standard first-line drugs while extensively drug-resistant TB occurs when resistance
to second-line drugs develops in addition to MDR-TB. The identification of XDR-TB in Tugela Ferry,
KwaZulu-Natal, South Africa in 2006, highlighted the inadequacies of the National TB Control pro-
gram and emphasized the importance of infection control [24]. As a result of this outbreak, the treatment
guidelines of South Africa were revised in 2007 [20]. Ethambutol was replaced by terizidone for the treat-
ment of MDR-TB. To treat XDR-TB, amikacin/kanamycin, pyrazinamide and ofloxacin were replaced
by capreomycin, p-AS and moxifloxacin. These changes were implemented based on the assumption
that both capreomycin and p-AS have not been used extensively in South Africa and therefore resistance
to these drugs should be rare. Yet, a national survey conducted in 2008 in South Africa revealed that
20.2% of all notified TB cases of that year (13000) showed resistance to isoniazid and nearly half of
them (9.6% of all cases) were MDR-TB [25], indicating a 3-fold increase of MDR-TB cases since 2002
(3.1%). Furthermore, recent analyses of M. tuberculosis strains revealed mutations in the inhA promoter,
katG, rpoB, embB, pncA, rrs and gyrA genes that caused resistance to isoniazid, ethionamide, rifampicin,
ethambutol, pyrazinamide, streptomycin, amikacin, capreomycin and ofloxacin [26, 27, 28, 29, 30, 31].
These findings implied the emergence of totally drug resistant (TDR)-TB.
Thus far resistance to p-AS has not been reported making p-AS one of the most important anti-TB drugs
in South Africa. The primary role of NATs in activating and/or deactivating a large and diverse number
of aromatic amines and hydrazine drugs makes them important in clinical pharmacology and toxicology
[32]. Human NAT1 catalyses the N-acetylation of p-AS used as part of the TB treatment regime in South
Africa. This makes NAT1 an important enzyme of research in the fight to control and treat TB in South
Africa.
1.3 Single nucleotide polymorphisms (SNPs)
Research has shown that single nucleotide polymorphisms in genomic DNA of NAT1 can change the
amino acid sequence [33, 34, 35, 36, 37]. This can destabilize the enzyme structure and negatively affect
the function of NAT1. A point mutation or single base substitution is a mutation that replaces a single
nucleotide with another, or leads to deletion or insertion of a base pair. Point mutations can be catego-
5
 
 
 
 
rized by the type of replacement or by function. For example purine-purine (or pyrimidine-pyrimidine)
replacements are termed transitions. Transversions are replacements of a purine by a pyrimidine and vice
versa. Two of three SNPs involve replacement of cytosine (C) with thymine (T) [38]. Functionally, point
mutations can be defined as nonsense, non-synonymous and synonymous mutations. Nonsense mutations
generate stop codons or a nonsense codon and produce a truncated, usually non-functional peptide chain.
Non-synonymous mutations introduce a different amino acid, whereas synonymous mutations code for
the same amino acid. Non-synonymous mutations may be either conservative, replacing the amino acid
by a closely related one, or non-conservative, in which an amino acid is replaced by another with different
properties.
Single nucleotide polymorphisms are point mutations that occur in at least 1% of a population. About
90% of sequence variations in humans involve differences in single nucleotides [38]. They occur every
100 to 300 bases in the human genome. SNPs may occur in coding regions (exons), non-coding regions
(introns) or 3’ and 5’ untranslated regions (UTRs). SNPs outside of protein-coding regions may affect
gene splicing, transcription factor binding or the sequence of non-coding RNA [39] and is referred to as
an expression SNP (eSNP). Point mutations within the coding region, non-conservative non-synonymous
mutations in particular, can affect the stability or folding of a protein and hence may change its function
[40].
1.4 Polymorphisms of human NAT1
The NAT1 isozyme was initially considered genetically invariant due to its substrate specificity for p-
AS and other drugs. It has now been shown to be subject to polymorphisms [41, 42], which can affect
the activity of NAT1 towards p-AS and para-aminobenzoic acid (p-ABA) [6, 14, 15, 43, 44, 45, 46].
Experimental laboratory analysis is the best method for the assessment of functional effects of nsSNPs.
The effects of a number of human NAT1 SNPs in the coding region and 3’-untranslated region have been
explored experimentally (Table 1.1). NAT1*4 has historically been designated "wild-type" because it
is the most common occurring allele in some but not all ethnic groups (the designation of "wild-type"
allele is somewhat arbitrary and is dependent upon the ethnicity of the population studied). Relative to
6
 
 
 
 
NAT1*4, the reference allele, SNPs were found to increase or decrease NAT1 activity resulting in rapid
or slow acetylation phenotypes.
1.5 Functions of human NAT1 and NAT2
The human NAT enzymes perform both bioactivation and bioinactivation reactions [55]. Though both
catalyse the acetylation of xenobiotics, they have a largely distinct substrate profile that overlap only to
some degree. The differences in substrate specificity are due to interactions within the active site cleft
[56] and the C-terminal region [48]. Residues 124-129 [16] together with the C-terminal domain are
involved in interactions with substrates at the active site cleft (Figure 1.2).
Minchin [57] and Ward [58], demonstrated that human NAT1 participates in the metabolic breakdown of
folate by acetylating the folate catabolite para-aminobenzoyl glutamate (p-ABAGLU). Other compounds
like p-AS are also metabolised by human NAT1 [59]. Human NAT2 by contrast metabolizes the drugs
hydrazide, hydralazine, phenelzine and arylamine drugs such as procainamide and sulphamethazine [60].
Despite differences in substrate selectivities, some substrates such as 2-aminofluorene are metabolised
by both NAT1 and NAT2 enzymes [61] and NAT1 has been known to metabolise compounds primarily
metabolised by NAT2 in slow acetylators [62].
Clinicians in South Africa are currently using p-AS as part of the treatment regime because of drug
resistance in TB. It is important to expand the work on NAT1 given the paucity of data for NAT1 function
relative to NAT2 and the fact that NAT1 metabolizes p-AS.
1.6 Protein structures and residue interactions
The function and chemical properties of a protein are determined by its three-dimensional (3D) structure.
This 3D-structure begins with a linear arrangement of the amino acids (its primary structure) and pro-
gresses through several protein folding steps creating secondary, tertiary and quaternary structures of the
protein [63].
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1.6.1 Residue interactions
Protein amino acid interactions are mostly non-covalent and include the interactions discussed below.
Hydrophobic interactions occur between non-polar residues and give the largest single contribution to
protein stability [63]. Hydrogen bonds (H-bonds) also contribute to protein stability. Hydrogen bonds
are formed when a positively charged hydrogen atom covalently attached to an electronegative atom
(the donor) interacts with another electronegative atom (the acceptor). Repulsion forces appear between
electron orbitals of atoms and are defined by their van der Waals radii. CH...pi-interactions are weak polar
interactions involving pi-system acceptor groups [64]. They are largely caused by dispersion of charges
and partly from charge-transfer and electrostatic forces. CH..pi-interactions between aromatic groups are
found mostly in the interior of the protein. Chi..pi-interactions between hydrophilic residues are located
at the surface of the protein. Aromatic-aromatic interactions (pi-pi stacking) also occur in proteins and are
non-covalent interactions between aromatic rings. These interactions are important in protein folding,
base stacking of DNA nucleotides and molecular recognition. Besides the above mentioned non-covalent
interactions, the structure of proteins are also stabilized by covalent bonds. Disulfide bridges are formed
between pairs of cystyl residues. Electrostatic forces occur between residues with net opposite charges,
known as salt bridges or between two dipoles, each formed from the asymmetric distribution of electrons
within the residues.
1.6.2 The secondary structure
Regular arrangement of the linear polypeptide chains (secondary structure) with repeating values for the
φ and ψ torsions angels and main-chain hydrogen bonding results in two major secondary structure types,
α-helices and β -strands [63, 65]. The inner part of the α-helix is formed by the coiled polypeptide main-
chain and the surface by the side-chains projecting outwards in a helical arrangement. It is stabilized
by hydrogen bonds between the carboxyl group of the amino acid residues of the main-chain and the
amino group of the residue located four residues away in the amino acid sequence, with repeated torsion
angle values of about - 60° for φ and -40° for ψ [63, 65]. It is also stabilized by the van der Waals
interactions generated by the close packing of the backbone atoms. The various amino acid residues
along a polypeptide chain have different tendencies to form α-helices [63, 66]. For example, A, L, F,
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W, M, H and Q stabilize α-helices, whereas S, I, T, Q, D and G have a destabilizing effect and P and
hydroxyproline create sharp bends in the helices that destroy the helices. Other types of helices with
hydrogen bonds between residues residing closer together (n + 3) or farther apart (n + 5) are also known
[63]. The former is called the 310-helix, with 3 residues per turn and 10 atoms between the donor and
the acceptor in the hydrogen bond. The dipoles of the 310-helix are not so well aligned as in the α-helix,
i.e. it is a less stable structure and side chain packing is less favorable. The later (n + 5) is denoted as the
pi-helix [63].
The other major secondary structure is the β -strand. A β -strand is basically made of a 5 to 10 residue unit
of the polypeptide whose backbone is almost fully extended, with rotation angle values of about -120° for
φ and 140° for ψ [63]. A β -strand has two residues per turn and a translation of 3.4 Å per residue and is
not a stable structure [63]. β -strands therefore, tend to interact with other β -strands that either belong to
other regions of the same polypeptide chain but are apart in the primary structure or are present in different
polypeptide chains. Adjacent β -strands are stabilized by hydrogen bonds formed between the carbonyl
groups of one β -strand and the amino groups of another β -strand and vice versa. The corresponding
structures contain alternate Cα atoms lying a little above and a little below the plane of the sheet and are
called β pleated sheets. The sheets contain on average 2 to 6 β -strands and are designated either parallel,
anti-parallel or mixed β -sheets depending on the relative direction of the strands. Similar to α-helices,
some amino acid residues have a higher tendency to form β -strands than others [63, 66]. Thus V, I and
T, which contain branched side-chains and the three aromatic residues F, Y and W favour the formation
of β -strands. In contrast, E, Q, L, D, N, C and P exhibit low propensity to form β -strands.
A number of non-repetitive well-ordered structures are present in protein chains in addition to the major
secondary structures. These non-repetitive structures occur mostly at the surface of proteins and fre-
quently contain G and P residues due to the special conformational properties of these two residues. The
non-repetitive structures are mainly turns, connections and loops that allow formation of structural mo-
tifs that constitute super-secondary structure. Examples of these motifs are the helix–loop–helix motif,
consisting of two α-helices joined by a loop region and the hairpin β motif, composed of two adjacent
antiparallel β -strands connected by a loop.
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1.6.3 Tertiary and quaternary structures
The tertiary structure is also determined by the packing of the α-helices and β -strands, which combine
to form units called domains [67, 68]. These domains form the fundamental elements of the globular
polypeptide chains with regards to function. The polypeptide chain with secondary structures may occur
as a folded structure [69, 67, 68]. The tendency of hydrophobic groups to minimize their contact with
water and hence occur on the interior while hydrophilic groups occur on the exterior provide the fold-
ing force resulting in the lowest energy conformation. This lowest energy conformation is the tertiary
structure. The tertiary structure (native conformation) of a protein is its biologically active conformation.
The major stabilizing force responsible for the compact three-dimensional form of a protein is hydropho-
bic interactions between non polar side chains of amino acids. Polar side chains undergoing hydrogen
bonding and ionic interactions also stabilize the tertiary structure.
Additionally, Van der Waals interactions and disulphide bonds contribute towards the stability of the
native protein structure. Many proteins are made up of two or more polypeptide chains, called subunits or
monomers, which represent the quaternary structure. The subunits are folded independently and interact
at surfaces complementary in shape and physical properties.
The interactions between two identical subunits (homo-dimers) are either isologous or heterologous. In
isologous associations the same surfaces on both subunits are utilized, whereas heterologous interactions
involve two different sites [63]. Non-polar interactions occur preferentially at the centre of the interfaces
while hydrophilic groups are often located at the surface allowing interaction with polar solvents. As is
the case with crystals, the asymmetrical packing of subunits minimizes the free energy in the aggregated
form [63].
Thus any amino acid changes that occur in the protein structure due to nucleotide variation can affect
residue interactions and stabilise or destabilize the structure and subsequently affect protein function.
1.6.4 Structural features of human NATs
Human NATs like any other protein, have a unique structure that relates to its function. Residues involved
in substrate-binding by van der Waals contacts include F37, F93, L209, F217, S216 and L288 (Fig 1.4)
11
 
 
 
 
[56]. Hydrogen bonds to CoA involve the amide nitrogens of T103 and G104 in the β3-β4 loop and the
hydroxyl groups of S214 (or Y214 in NAT2) from the β9 and the β9-β10 loops respectively. The N6 of
the adenine ring of CoA form a single hydrogen bond with side chain of S287. This ring makes contact
with the hydrophobic residues F125 and V98. The hydrophobic surface of the substrate-binding site of
human NAT1 is formed by the aromatic ring of F125 and the side chain of V93 including the hydrophobic
residues I106 and F217 (Fig 1.4). The substrate-binding site in NAT1 is smaller (162Å) than NAT2
(257Å) as a result of two important residue substitutions at positions 127 and 129 [56]. In NAT1, these
residues are R127 and Y129 while NAT2 carries S127 and S129. Another important substitution to the
substrate-binding site occurs at position 93 where NAT1 exhibits valine and NAT2 carries phenylalanine.
In NAT2 this amino acid leads to a “lip” in the van der Waals surfaces of the binding site making it more
selective for substrates that can fit this feature.
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Figure 1.4 Functionally important residues of NAT1 protein
The catalytic triad residues comprise C68, H107 and D122, which are highlighted in red at the top left corner. The substrate,
p-AS binding residues I106, H107 and R127 are displayed in red at the top right corner. The residues critical for CoA binding
are displayed in red at the bottom left (T103, G104, Y208 and S214). At the bottom right corner are other substrates binding
hydrophobic residues (F37, V93, L209, V216, F217, F288).
A 17-residue insertion (167 to 183) in human NATs represents a striking difference between human and
prokaryotic NATs [56]. This insertion is proposed to contribute to the stability of the human enzymes by
extending the 4-stranded anti-parallel β -sheets in prokaryotes (domain III) by a short β -strand [56]. It
buries the carboxy terminus of the NAT protein and forms hydrogen bonds with residues from β14 and
β15 strands , β14-β15, β9-β10 and α6-β14 loops [56]. The conserved catalytic triad of C68, H107 and
D122 in human NATs is structurally superimposable with that of prokaryotic NATs [56].
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1.7 Project rationale and objectives
1.7.1 Rationale
A major interest in human genetics is to distinguish between functionally neutral mutations and those that
contribute to disease [70] as amino acid substitutions account for approximately half of the known genes
responsible for inherited diseases [39]. Several nsSNP variants have been functionally characterised
particularly in human NAT1 [35, 49, 50, 53, 54, 71, 72, 73, 74, 75]. However, such experimental studies
are expensive and time consuming. Computational analysis can discriminate between neutral SNPs which
constitute the majority of genetic variation and SNPs likely to affect protein function [76]. This helps to
inform experimentalists on prioritizing SNPs for functional studies and to deepen the understanding of
genotype-phenotype relationships.
Computational methods have been developed to predict the impact of amino acid substitution on the
structure and function of a protein [70, 77, 78, 79, 80]. These algorithms are based on sequence conser-
vation over an evolutionary period, the physical and chemical properties of the substituted amino acids
and/or protein structural domain information. The Sorting Intolerant From Tolerant (SIFT) algorithm is
based on sequence identity of related genes and domains over evolutionary time. It also considers the
characteristics of the amino acid residues when predicting the effect of the substitution. The Polymor-
phism phenotyping version 2 (POLYPHEN-2) algorithm takes into account the sequence conservation,
the amino acid characteristics and the location of the substitution within functional domains of the protein
available in the annotated database of SWISS-PROT [81].
Ng and Henikoff [70], used SIFT to predict the effects of nsSNPs on several proteins in SWISS-PROT or
TrEMBL. In their analysis, 69% (3626/5218) of the substitutions known to be involved in disease were
predicted as damaging. Furthermore, SIFT predicted that 18 of 22 nsSNPs found in diseased patients
affect protein function and that 9 of 10 nsSNPs found in control patients are functionally neutral. Sim-
ilarly, Xi and colleagues [78] analysed effects of amino acid substitutions on protein activity of DNA
repair genes using SIFT and POLYPHEN. For the above study, SIFT classified 226 of 508 (44%) as
intolerant while POLYPHEN classified 165 of 489 (34%) as possibly damaging. The results from the
two algorithms were in agreement, with concordance of predicted impact observed for ~62% of the vari-
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ants [78]. Johnson and colleagues [80] observed a similar high concordance of 73% between SIFT and
POLYPHEN predictions for nsSNP effects in genes involved in steroid hormone metabolism and re-
sponse. Di and colleagues [76] carried out analysis on 247 nsSNPs using SIFT and POLYPHEN. In the
above study, scatter graphs showed a negative correlation with a Spearman’s rank correlation coefficient
of -0.709 (p≤ 0.01) illustrating a significant concordance between the prediction scores from SIFT and
POLYPHEN algorithms. These studies together with others [77, 79] provide evidence that SIFT and
POLYPHEN can differentiate between damaging and neutral nsSNP in two-third cases. Given that SIFT
and POLYPHEN-2 can not correctly predict over 25% of nsSNPs [76, 78], it is important to expand the
assessment of the functional effects of nsSNPs using other methods such as homology modelling, Gibbs
free energy change and residue interactions.
Human arylamine N-acetyltransferase 1 (NAT1) is a xenobiotic metabolizing enzyme that affects the bi-
ological activity and toxicity of compounds including tuberculosis (TB) drugs. NAT1 catalyses either the
acetyl-CoA dependent N-acetylation of primary aromatic amines and hydrazines (usually deactivating)
or the O-acetylation of their N-hydroxylated metabolites (usually activating) [7]. NAT1 specifically acts
on para-aminosalicylic acid (p-AS) which is used in TB treatment [16], a primary drug in TB treatment
in South Africa [20, 82]. Polymorphisms in NAT1 divide individuals into slow, intermediate and rapid
acetylators. Rapid acetylators are at risk of not responding to treatment while slow acetylators are at risk
of drug toxicity.
Twenty-three SNPs that affect protein function [35, 36, 37, 47, 49, 50, 52, 53, 54, 71, 72], have been
detected in NAT1 mostly among Caucasians [49] and more recently have been detected in the South
African mixed ancestry population in the Western Cape region. Eleven novel nsSNPs in NAT1 have also
been detected in the South African mixed ancestry population in the Western Cape region. The effects
of these 11 nsSNPs on the function of NAT1 are not known. Previous studies have shown that functional
effects of nsSNPs can be predicted computationally [83, 84].
This project proposes to computationally test the effects of 11 novel nsSNPs on the structure and function
of NAT1 using structural analysis including homology modelling, residue interactions, stability calcula-
tion and solvent accessibility in addition to the routinely used SIFT and POLYPHEN-2 algorithms. Our
results will allow us to prioritize the SNPs for experimental analysis.
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1.7.2 Aim and Objectives
The aim of this study is to assess the value of supplementing the routinely used SIFT and POLYPHEN-
2 algorithms with homology modelling, relative solvent accessibility, Gibbs free energy change, SNP
conservation and residue interactions, to predict the effects of nsSNPs on the function of a protein (i.e.
NAT1).
Objectives:
1. To assess the functional effects of 11 NAT1 nsSNPs previously identified in Caucasians and re-
cently confirmed in a South African population using SIFT and POLYPHEN-2 algorithms, ho-
mology modelling, relative solvent accessibility, Gibbs free energy change, SNP conservation and
residue interactions analyses.
2. To assess the functional effects of 11 novel NAT1 nsSNPs identified in a South African population,
using the SIFT and POLYPHEN-2 algorithms, homology modelling, relative solvent accessibility,
Gibbs free energy change, SNP conservation and residue interactions analyses.
16
 
 
 
 
Chapter 2
MATERIALS AND METHODS
2.1 MATERIALS
The functional effects of nsSNPs are routinely assessed with the SIFT and POLYPHEN-2 algorithms.
These can be complemented with structural analysis. Computational analysis involving hydrogen bond
or salt bridge determination, solvent accessible surface area calculation and stability changes, would
require SNP residues modelled in the structure of the protein. This can be achieved with homology
modelling.
2.1.1 Sorting Intolerant From Tolerant (SIFT) prediction server
A useful tool in assessing the functional effects of amino acid substitutions is Sorting Intolerant From
Tolerant (SIFT). SIFT aims to predict whether an amino acid substitution will affect the function of a
protein considering the amino acid sequence of the protein and physical properties of the amino acids
[85]. SIFT also requires homologue information from phylogeny analysis or a sequence alignment. SIFT
can use position-specific information obtained from sequence alignments collected through PSI-BLAST.
SIFT assumes that conserved amino acids are functionally important. Changes at well-conserved posi-
tions tend to be identified as deleterious. Substitutions of residues with amino acids of similar character
will generally be accepted as neutral. SIFT is a multi-step procedure:
1. use a group of sequences to search for closely related sequences,
17
 
 
 
 
2. then chooses closely related sequences that may have a function similar to the query sequence,
3. generates the alignment of the chosen sequences, and
4. calculates normalized probabilities for all possible substitutions from the alignment.
The reliability of predictions of the functional effects of nsSNPs depends on the diversity of the sequences
in the alignment. Closely related sequences will indicate many conserved positions. SIFT will hence
predict most substitutions to affect protein function. This may lead to a high proportion of false positive
errors where functionally neutral substitutions are predicted to be deleterious. To account for these false
errors, SIFT calculates the median conservation value to quantify the diversity of the sequences in the
alignment. The degree of conservation is calculated for each position in the alignment and the median of
these values is obtained in logarithmic terms. Median conservation values range from 4.32, for a perfectly
conserved residue to 0.00, when all 20 amino acids are observed at a position with equal probability. By
default, SIFT generates alignments with a median conservation value of 3.0. However, the recommended
range is 2.75 to 3.25. Predictions based on sequence alignments with higher median conservation values
are less diverse and will have a higher false positive error.
Substitutions at positions with normalized probabilities below 0.05 are predicted to be deleterious (affect
protein function) and those greater than or equal to 0.05 are predicted to be tolerated [85].
The databases employed in SIFT analysis include UniRef (http://www.ebi.ac.uk/uniref/), UniProt-SwissProt
(http://web.expasy.org/docs/swiss-prot_guideline.html), UniProt-TrEMBL (http://www.ebi.ac.uk/uniprot/)
and NCBI non-redundant database (http://www.ncbi.nlm.nih.gov/). The algorithm and instructions for
analysis of amino acid substitutions are available at http://sift.jcvi.org/.
2.1.2 Polymorphism phenotyping version 2 (POLYPHEN-2) prediction server
Polymorphism phenotyping version 2 (POLYPHEN-2) is a computer programme that attempts to pre-
dict the effects of non-synonymous mutations on protein function [86]. POLYPHEN-2 uses sequence,
phylogenetic or evolutionary information and works best if structural information is available as well. In
addition to conservation scores, it adds physico-chemical differences and structural features of the poly-
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morphic variants to enable the prediction of functional effects of amino acid change. It uses the following
sequence-based and structure-based predictive features. The predictive features include:
• position-specific independent count (PSIC) score for the wild-type allele,
• differences of PSIC scores,
• number of distinct amino acids observed at the position of the multiple alignment,
• position of the mutation within/outside a protein domain as defined by Pfam,
• congruency of the mutant allele to the multiple alignment,
• sequence identity with the closest homologue deviating from wild-type allele,
• whether the variant occurred as transition in CpG dinucleotide context,
• normalized accessible surface area of the amino acid residue,
• crystallographic β -factor and
• change in accessible surface area propensity for buried residues.
The input is the amino acid sequence of a protein or the SWALL database ID or accession number,
together with sequence position and two amino acid variants characterizing the polymorphism. It pre-
dicts a substitution to be damaging i.e. to affect protein function or benign (i.e. most likely lacking
any phenotypic effect). The POLYPHEN-2 scores range from 0 to 1. A variant with less than or equal
to 0.5 score is considered benign while a variant score above 0.5 means the variant is damaging [86].
The SWALL database is located at http://srs.ebi.ac.uk/srs6bin/cgi-bin/wgetz?-page+LibInfo+-newId+-
lib+SWALL. Additional information and instructions for analysis of amino acid substitutions are avail-
able at http://genetics.bwh.harvard.edu/pph2/.
2.1.3 CLUSTALW2 multiple sequence alignment server
CLUSTALW2 is a web-based tool used to align DNA or proteins sequences [87].
19
 
 
 
 
Three or more sequences to be aligned are entered directly into the sequence input window. However,
a file containing three or more valid sequences in the right format can be uploaded and used as input
for the multiple sequence alignment. A sequence type, alignment type, protein weight matrix, gap open,
gap extension are all options in CLUSTALW2 to ensure quality alignment. Detailed information on
CLUSTALW2 is available at http://www.ebi.ac.uk/Tools/msa/clustalw2/.
2.1.4 Homology modelling and MODELLER software
Homology modelling is a computational method to predict the three-dimensional structure of proteins
based on related experimentally elucidated protein structures. Protein folds are more highly conserved
than amino acid sequences. Proteins with significant sequence homology are generally assumed to be re-
lated and to share a common core structure [88]. This means that the structure of a protein can be inferred
from proteins of known structure. Typically, homology modelling requires the following information:
1. the sequence of the protein of unknown structure or the “target sequence”.
2. a coordinate file describing the three-dimensional arrangement of atoms derived experimentally
by techniques such as X-ray crystallography or nuclear magnetic resonance spectroscopy or the
“template”; and
3. an alignment between the target sequence and the template sequence.
MODELLER is a computer program that generates three dimensional models of proteins by attempt-
ing to accommodate spatial restraints. It is commonly used for homology or comparative modelling of
protein structures. It allows the user to provide sequence alignment of a sequence to be modelled with
known related structures and then calculates a model with all non-hydrogen atoms [89]. MODELLER
also performs other tasks such as optimization of the protein structure model with respect to a defined
objective function.
The inputs to MODELLER are restraints in the spatial sequence of amino acids and ligands to be mod-
elled. The output is a 3D model that satisfies defined restraints. MODELLER aligns the target sequence
with the template structure and builds 3D models of each target/template alignment producing the num-
ber of models specified. The best model can be selected with discrete optimized potential energy (DOPE)
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and GA341 assessment scores. DOPE is a statistical potential used to assess homology models in protein
structure prediction. DOPE is based on a reference state that corresponds to noninteracting atoms in a ho-
mogeneous sphere with the radius dependent on a sample native structure. DOPE is implemented in the
MODELLER software and is used to assess the energy of the protein model generated by MODELLER.
The DOPE profiles of proteins may be plotted with a graphical tool such as GNUPLOT [90] a portable
command-line driven graphing utility or plotting engine for Linux, OS/2, MS Windows, OSX, VMS and
other platforms.
2.1.5 PROCHECK Software
Protein structures derived from experimental data as well as those obtained from “model building” are
subject to many sources of errors. The PROCHECK suite of programs [91] provides a detailed check
on the stereochemistry of a protein structure and outputs a number of plots in post script format and a
comprehensive residue-by-residue listing with an assessment of the overall quality of the structure as
compared to refined structures of the same resolution. It also highlights regions that may need further
investigation and categorizes these regions into most favoured regions, additionally allowed regions,
generously allowed regions and disallowed regions. A good quality structure would be expected to
have over 90% percent of its residues within the most favoured regions (http://www.ebi.ac.uk/thornton-
srv/software/PROCHECK/.
2.1.6 UCSF CHIMERA
The structure of a protein reveals more information about function than the amino acid sequence alone.
This structure is, however, determined by countless interactions of amino acid residues with each other.
These interactions as mentioned in section 1.6, include hydrogen bonding, hydrophobic interactions,
ionic or electrostatic interactions, van der Waals interactions and disulphide bonds, among main chain or
side chains of residues. Hence, any changes due to mutations that significantly disrupt these interactions
would affect the structure of the protein and consequently its function.
The molecular graphics program UCSF CHIMERA [92] includes a suite of tools for interactive analyses
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of sequences and structures. Structures automatically associate with sequences in imported sequence
alignments. CHIMERA allows the superimposition of structures without pre-existing sequence align-
ment. CHIMERA generates structure-based sequence alignments from superpositions of two or more
proteins. It has a multi-scale extension, that provides the functionality to visualize large-scale molec-
ular assemblies such as proteins while the multalign viewer, permits multiple sequence alignments and
associated structures to be viewed (http://www.cgl.ucsf.edu/chimera/).
2.1.7 FOLDX Software
Protein structures are stabilized by non-covalent inter-molecular interactions between amino acid side
chains. All biological processes depend on proteins being stable and in the appropriate folded conforma-
tion. The impact of amino acid substitutions on the stability of proteins may be estimated by calculating
the Gibbs free energy changes associated with such substitutions. Such energy changes indicate stabi-
lization or destabilization of the approximate protein native structure. FOLDX attempts to quantify the
impact that substitutions have on the stability of proteins and protein complexes using an empirical force
field [93]. Given a full atomic description of the structure of the protein, it calculates free energy change
in kcal/mol of the wild-type (WT) and variant type (VT). The different energy terms used by FOLDX for
calculating the free energy are weighted using empirical data from protein engineering experiments [93].
The basic analysis performed is the calculation of Gibbs free energy of folding. The following are
options : temperature (K), water, pH, ionic-strength, metal and vdWDesign. Amino acid substitutions
with Gibbs free energies lower than the zero are inferred to be stabilizing while those with free energies
larger than zero are destabilizing [93]. FOLDX attempts to optimize the conformation of residues with
bad torsion angles, van der Waals clashes or total energy before calculating the free energy changes
(http://foldx.crg.es/).
2.1.8 NACCESS Software
NACCESS calculates the accessible surface area of a molecule provided as a PDB format file [94]. It
calculates the atomic accessible surface area defined by rolling a probe of given size over a van der Waals
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surface. The program accomodates up to 20000 atoms and allows the user to change the probe size and
atomic radii. It genrates 3 files: atomic accessibility file (.asa ), residue accessibility file (.rsa ) and a log
file (.log). http://www.bioinf.manchester.ac.uk/naccess/.
2.2 METHODS
2.2.1 Sequence Data Acquisition
2.2.1.1 SNPs
Information for 22 nsSNPs in the coding region of human NAT1 identified in the mixed population in
South Africa were provided by Dr. Cedric Werely at Stellenbosch University (Table 2.1). Of the 22
nsSNPs, 11 matched published nsSNPs while the other 11 are novel and are all located near the 3’-
untranslated region of the NAT1. The effects of eight of the 11 published nsSNPs have previously been
analysed structurally by Walraven and colleagues [83]. These 8 nsSNPs were used as an internal control
to verify the methodology of Walraven and colleagues and to validate our methodology. The remaining
3 published nsSNPs and the 11 novel nsSNPs were analysed as described in this chapter and Fig 2.1.
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Table 2.1 List of nsSNPs and the associated amino acid changes
SNP Status NAT1 nsSNPs (Gene Positions) Amino Acid Substitutions
Published C190T R64W
G350C R117T
G445A V149I
G497C R166T
G498C E167Q
G560A R187Q
A613G M205V
T640G S214A
A752T D251V
G781A E261K
A787G I263V
Novel A1017T T193S
T1046G F202V
A1069C Q210P
G1125C D229H
T1132G V231G
T1144C V235A
C1159G T240S
G1165T R242M
A1174T N245I
T1217G S259R
G1230A E264K
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Figure 2.1 Methodology flow chart
The effects of nsSNPs on enzyme function were analysed with SIFT and POLYPHEN-2, homology modelling, relative sol-
vent accessibility, Gibbs free energy change, SNP conservation and residue interactions. The 22 nsSNPs in human NAT1
were homology modelled using MODELLER. The models with the lowest DOPE scores, were evaluated with PROCHECK
and their DOPE profiles plotted with GNUPLOT. The evaluated models were used for solvent accessibility calculation with
NACCESS, Gibbs free energy change with FOLDX and hydrogen bonds or salt bridge determination with CHIMERA. These
calculations provide evidence for the structural and hind functional effects of a nsSNP. Sequences of human NAT1, human
NAT2 and four prokaryotic NAT1s were aligned with CLUSTALW2 and optimized with CHIMERA to identify functionally
important residues. Green marks data used, blue the tools used and red the results.
2.2.1.2 Proteins
The amino acid sequences of human NAT1, NAT2 and NAT1 of M. marinum, M. bovis, M. tubercu-
losis and M. smegmatis were retrieved from the Universal Protein Resource (http://www.uniprot.org;
Uniprot). The search term “human arylamine N-acetyltransferases” was used to retrieve the FASTA
format sequences of both human NAT1 and NAT2 while “arylamine N-acetyltransferases” was used to
search for the other related NATs (i.e. prokaryotic NATs). In this work, the SNP containing sequences
were obtained by replacing each wild-type amino acid with the corresponding variant (i.e. the nsSNP)
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as indicated in Table 2.1. These modified sequences were the “targets” and the PDB crystal structure of
human NAT1 was the “template” (hereafter referred to as wild-type structure) in the homology modelling
analysis.
2.2.2 SIFT and POLYPHEN-2 analysis
Two on-line servers were used: the SIFT program [85] and POLYPHEN-2 program [95] to predict the
functional impact of the nsSNPs.
A FASTA NAT1 protein sequence and a file containing the wild-type and SNP residues were uploaded to
the SIFT server. The input NAT1 protein was searched against the UNIREF release April (2011) database
with default parameter for median conservation of sequence (see section 2.1.1 for definition). Sequences
in UNIREF that had similarity more than 90% to NAT1 were excluded from the SIFT predictions to
obtain acceptable median conservation levels (2.75-3.25) as suggested by the authors.
The FASTA formatted NAT1 protein sequence was submitted to the POLYPHEN-2 server. The position
of each amino acid wild-type and variant corresponding to each of the 22 NAT1 nsSNPs were specified.
2.2.3 Sequence conservation analysis
Residues critical to the structure and function of proteins are mostly highly conserved [96]. Changes
or substitutions of such residues can lead to significant consequences for the structure and hence func-
tion of the protein. Thus the conservation of a residue gives information about its likelihood of affect-
ing the structure and function when replaced by a different amino acid. CLUSTALW2 [87] and UCSF
CHIMERA 1.5.3 [92] were used to align and optimize sequences and visualize the conserved residues
respectively.
2.2.4 Structural analysis
As part of expanding our assessment of the functional effects of NAT1 nsSNPs, our structural analysis in-
cluded (a) homology modelling, (b) residue interactions analysis, (c) determination of Gibbs free energy
changes associated with the nsSNPs and (d) solvent accessibilities calculations.
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2.2.4.1 Homology modelling
The crystal structure of each nsSNP sequence was modelled with MODELLER 9.9 [89] using the wild-
type (WT) NAT1 (PDB code: 2PQT) as a template. Each SNP sequence in PIR format was then aligned
with the template using the MODELLER align2d() to construct the “target-template” alignment.
The automodel class of MODELLER was then used to generate 10 3D models (hereafter referred to as
“variant structures”) of each target-template alignment and selection of the “best” model with the lowest
DOPE scores chosen. DOPE scores were obtained using MODELLER “assess_methods with DOPE
and GA341 assessment scores” option. The DOPE potentials for best models and WT were evaluated
with MODELLER assess_dope() command. Four non-physiological residues at the N-terminus of NAT1
PDB crystal structure were removed before calculating the DOPE potential of the WT structure. Energy
profiles of all variant (VT) structures are plotted against the WT structure energy profile as DOPE plots
using GNUPLOT and structures were analysed visually using the UCSF CHIMERA 1.5.3 [92].
2.2.4.2 Evaluation of modelled structures
PROCHECK [91] was used to check the stereochemical quality of all structures (WT and VT) using WT
resolution of 1.78 Å.
2.2.4.3 Residue interaction determination
Hydrogen bonds and salt-bridges, were assessed using UCSF CHIMERA 1.5.3, with the “Command
Line” option and “FindHBond” function (Appendix A.1).
2.2.4.4 Protein structure stability calculation
Protein structures are stabilized by non-covalent intra-molecular interactions between amino acid side
chains and main chains. The impact of mutations on the stability of proteins may be tentatively quanti-
fied by estimating the Gibbs free energy changes associated with such mutations. Such energy changes
may reveal destabilization of the native structure of the protein and hence changes in function or cause
of disease [97]. Changes to the structure of a protein due to nsSNPs can be evaluated using 2 approaches
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[97], namely, determining changes to the 3D-structure predicted from crystallography studies and mea-
suring changes in protein stability by unfolding energy. Functional alterations due to structural changes
could potentially be derived from either of the two methods. Estimating protein stability in terms of un-
folding energy changes is simpler and less expensive [97]. Gibbs free energy of protein unfolding energy
is calculated using the equation ∆∆G= ∆Gmutant – ∆Gwild-type [97] for example as in FOLDX.
To assess the effect of the mutations on the stability of NAT1, FOLDX 3.0 β 5.1c [93] was used to
calculate the change in Gibbs free energy associated with the substitutions (see Appendix A.2).
2.2.4.5 Solvent accessibility calculation
Intramolecular hydrogen bonding in proteins is suggested to depend on the accessibility of the donors
and acceptors to water molecules [98]. NACCESS 2.1.1 [94] was used to provide relative and absolute
solvent accessibilities per residue (Appendix A.3).
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Chapter 3
RESULTS AND DISCUSSION
The human NAT1 enzyme is a xenobiotic metabolizing enzyme which inter alia catalyzes the acetylation
of the anti-tuberculosis drugs para-aminosalicylic acid and para-aminobenzoyl glutamate. The identifi-
cation and characterization of SNPs in genes of drug-metabolizing enzymes such as NAT1 is critical in
understanding differences in drug metabolism, therapeutic efficacy and inherited diseases of individuals.
It is therefore important to investigate the functional impact of SNPs on these enzymes.
This study provides a first step in this direction by predicting the effects of 11 novel nsSNPs on the
structure and function of human NAT1 using homology modelling, relative solvent accessibility calcu-
lation, Gibbs free energy change calculation, SNP conservation and residue interactions to augment the
commonly used SIFT and POLYPHEN-2 algorithms.
3.1 SIFT and POLYPHEN-2 analysis
Functional consequences of non-synonymous SNPs are routinely assessed using the SIFT and POLYPHEN-
2 algorithms. The results for 11 published and 11 novel nsSNPs in NAT1 are listed in Tables 3.1 (pub-
lished nsSNPs) and 3.2 (novel nsSNPs). SIFT predictions were based on 27 or 28 related sequences and
a median conservation scores of 3.04-3.05. A median conservation score of 2.75 to 3.25 is informative
(here 3.05) [85].
Both SIFT and POLYPHEN-2 predict the three published variants R64W, R166T and D251V and the six
29
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novel variants F202V, Q210P, D229H, V231G, V235A and N245I to affect the function of NAT1. The
variants R117T, V149I, E167Q, M205V, S214A, E261K, I263V (published), T193S, T240S and S259R
(novel) were predicted by both algorithms as having no effects on the function of NAT1. For the nsSNPs
R187Q (published), R242M and E264K (both novel) the algorithms showed contradictory results. Thus
SIFT and POLYPHEN-2 agree in this assessment of nineteen (8 published and 11 novel) nsSNPs or a
concordance of 86% for 22 nsSNPs compared to ~62% [78] and 73% [80] in earlier analyses.
Although useful in their potential to predict the functional consequence of nsSNPs, SIFT and POLYPHEN-
2 have limitations that affect their prediction accuracy. Firstly, SIFT and POLPHEN-2 rely on several
different databases for SNP information. When too few sequences are available for a particular gene
or when the sequences are closely related, a neutral variant may be predicted to affect protein function
[85, 99]. Databases with erroneous SNP reports and bias of the data towards disease-related allelic vari-
ants are likely to lead to an over prediction of the number of deleterious nsSNPs [86]. For example,
Ramensky et al. [86] predicted nsSNPs (grouped or categorized) to affect protein function for human
genome variation (HGV-base) entries and showed that for the category “Proven” nsSNPs (SNPs con-
firmed by independent and solid experimental verification) was 28.9%, the overall prediction rate for the
category “Suspected” nsSNPs (other SNP candidates) was 31.4% and for another “Proven” nsSNPs from
systematic studies on healthy individual was 27.6%. Similarly, Di et al. [76] collected data from 63 in
vitro and in vivo studies and found that the false negative predictions for SIFT and POLYPHEN were
43% and 33% respectively. Additionally, programs may identify base differences in a pseudogene as
SNPs in the functional protein affecting the accuracy of prediction tools [70]. However, as more genome
sequences become available SNP databases, should improve increasing their reliability [100, 101].
Errors may also arise because SIFT not accounting for mutations that affect transcription, translation,
splicing and other post-translational alterations [70]. Further, the prediction may appear incorrect due to
lack of association with altered phenotypes. SIFT and POLYPHEN-2 may be sensitive to an amino acid
substitution and predict it to be damaging to protein function. On the other hand, SIFT and POLYPHEN-2
may predict a deleterious substitution to be “tolerated or benign” which may not be an obvious phenotype.
This may be interpreted as a correct prediction although it is a recessive or undiagnosed deleterious
substitution. Another limitation of these algorithms is that variants combination are not assessed and
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the dependence of functional impact of a variant on genotype of other genes or on exposure risk is
not addressed [99]. One final restriction of SIFT and POLYPHEN-2 is that the algorithms are unable
to predict the impact of SNPs that occur outside of the coding region, such as promoter and enhancer
regions and splice sites that may affect protein levels or protein function.
3.2 Sequence conservation profile between human and prokaryotic NAT1 enzymes
As indicated, residues critical to the structure and function of proteins are mostly well conserved [96].
Substitutions of such residues will affect the structure and hence function of the protein. To assess the
conservation of NAT1 nsSNPs in humans and prokaryotes, we aligned 6 wild-type NAT1 proteins using
CLUSTALW2 and UCSF CHIMERA 1.5.3. The first 2 nsSNPs positions (64 and 117) are depicted in
Figure 3.1, which highlights residues 1 to 140 of NAT1. The remaining 20 nsSNPs are displayed in
Figure 3.2, which incorporates residues 141 to 288 (see arrows). Bacterial NATs shared between 26 and
29 % sequence identity to NAT1, while human NAT2 shares 81% identity with NAT1.
Residues 202, 205, 210, 231, 235, 242, 245, 251 and 261 are conserved in human NATs (red arrows,
Figure 3.2) but distinct from prokaryotic sequences. Residues conserved in all sequences include posi-
tions 166, 229 (yellow arrows, Figure 3.2) and R64 (black arrow, Figure 3.2). The wild-type residues
V149, R187, S214, S259 and I263 only occur in the human NAT1 sequence (green arrows, Figure 3.2).
Positions 172 to 188 of the human NATs are not present in prokaryotes. This region corresponds to
the 17-residue insert region unique to human NATs (Figure 3.2) and nsSNP position 187 occur in the
17-residue insert region of the human NATs (an R in NAT1 and Q in NAT2).
R64W, R117T and R166T variants
The same multiple sequence analysis indicates R64 and R166 to be conserved in all six sequences in-
dicating their structural and functional importance. Replacing basic R64 by tryptophan would affect
the function of NAT1. Similarly, substituting basic R166 with hydrophilic threonine would affect the
function of NAT1. The prediction of both algorithms for variants R64W and R166T are probably cor-
rect. The sequence alignment further indicated R117 to be conserved in human NATs but replaced by
33
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glycine in other species. This implies that R117 may be critical for NATs and hence substituting it with
threonine (T166) would have some significant functional impairment of NAT1 as predicted by SIFT and
POLYPHEN-2.
V149I, E167Q and R187Q variants
V149 only occurs in NAT1, it is replaced by isoleucine in NAT2 and proline in prokaryotic NATs. Sub-
stituting I149 for V149 may thus affect minimally the function of NAT1 as indicated by the algorithms.
Both human NAT sequences have Glu at position 167 replaced by aspartic acid or glycine in prokaryotic
NATs. No significant structural impact is thus expected when substituting by glutamine, an amino acid
of similar properties and supports the conclusion of SIFT and POLYPHEN-2. The variant R187Q, is
one of the variants with contradictory results reported by both algorithms. NAT1 R187 occurs in the
17-residue insert region absent in prokaryotic NATs. NAT2 however, has Q187. This may indicate that a
basic residue is functionally important at position 187 of NAT1 whereas an acidic residue is required for
NAT2. Hence substitution of Q187 in NAT1 may affect its function as predicted by the POLYPHEN-2
algorithm.
M205V, S214A and D251V variants
M205 only occurs in human NATs, while M. marinum and M. smegmatis have a glycine and M. tuber-
culosis and M. bovis an alanine at this position. The above residues are all hydrophobic and as such
substitution of hydrophobic valine, V205 may not have any effect on the function of NAT1 as predicted
by SIFT and POLYPHEN-2. The sequence analysis shows that S214 occurs in only NAT1 while NAT2
has T214. The prokaryotic sequences have alanine, glycine or threonine. This means that the posi-
tion accepts hydrophilic or hydrophobic residues for the function of the human NAT1. Substitution of
S214, by similar size alanine will therefore have no effect on NAT1 function as predicted by SIFT and
POLYPHEN-2. The residue D251 only occur in human NATs while 3 prokaryotic NATs possess R251
and one prokaryotic NAT possess L251. This implies charged residues are important in position 251.
Substitution of non-charged V251 in NAT1 would therefore affect its function as predicted.
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T193S, E261K and I263V variants
The sequence alignment indicates that E261 occur only in the human sequences while three prokaryotic
sequences possess threonine and one possess alanine. Substituting acidic E261 with basic K261 could
affect the function of NAT1. In position 263, there are four hydrophobic residues; one isoleucine, two va-
line residues and one alanine residue and two hydroxylic serine residues. Thus substituting hydrophobic
I263 for hydrophobic V263 in NAT1 is not expected to substantially affect the function of the protein. At
position 193 all sequences possess the hydrophobic residue threonine except M. marinum which possess
the hydrophobic serine. Thus substituted hydrophobic S193 should have no effect on NAT1 function.
F202V, Q210P and D229H variants
F202 is only conserved in the human NATs while the prokaryotic NATs possess the aliphatic amino acid
leucine. This implies that the residue F202 may not be critical for the structure and function within the
prokaryotic family but could play important roles in the structure of the human proteins. The substitution
of aromatic phenylalanine, F202V with aliphatic valine, V202 is expected to cause an effect on the
function of NAT1 due to differences in chemical properties as indicated by the algorithms. The residue
Q210 was observed to be conserved in only the human NATs with S210 in the prokaryotic NATs. It
could be inferred that Q210 is important for the structure of the eukaryotic NAT. Substituting Q210 with
the P210 (with an aliphatic heterocycle) is expected to affect the structure and function of NAT1 and this
agrees with the predictions of the algorithms. The alignment revealed that D229 is conserved among five
species except for human NAT2 where it is a glutamic acid residue. This is an indication that residue
position 229 accommodates acidic residues and could be important for the function of the NAT family and
residue D229 particularly for human NAT1. Its substitution by basic H229 would therefore presumably
affect the function of NAT1 as predicted by SIFT and POLYPHEN-2.
V231G, V235A and T240S variants
The residue V231 is only conserved in human NATs and may therefore not be critical for the structure
and function of the prokaryotic family but could be vital for the human NATs. In the position 231, the
prokaryotic NATs possess arginine. The substitution of G231 in NAT1 is therefore expected to affect the
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function of the protein as predicted by the algorithms. For wild-type residue V235, the alignment indi-
cates that it only occurs in human NATs while the prokaryotes possess S235, R235 or M235. Substitution
of A235 with similar properties to V235 is not expected to affect the function of NAT1 contrary to the
prediction of both algorithms. T240, from the sequence alignment, occur in only the human NATs while
the prokaryotes possess the hydrophobic residue, A240. Thus substituting hydrophobic T240 by another
hydrophobic S240 should not affect NAT1 function as predicted.
R242M, N245I, S259R and E264K variants
The variant R242M had contradictory results from both algorithms. The multiple sequence alignment
revealed that R242 is conserved among the human NATs but is a histidine residue in M. tuberculosis,
M. bovis, M. marinum and M. smegmatis. This implies the position accommodates aromatic or basic
residues. Substitution of a hydrophobic residue M242 is thus expected to have an affect on NAT1 pro-
tein function as predicted by POLYPHEN-2. The alignment indicates that N245 is conserved only in
the human NATs while the bacterial NATs have a glycine residue. The substitution of asparagine with
hydrophobic I245 could affect NAT1 function as predicted. The residue position 259 is highly variable
according to the multiple sequence alignment. The position is occupied by serine residue in human
NAT1, human NAT2 possess a threonine residue, M. smegmatis possess lysine residue while M. tubercu-
losis, M. bovis and M. marinum all possess a valine residue. Hence the sequence alignment suggests that
substitution of hydroxylic residues in the human NATs would be accepted without change in NAT1 func-
tion. The replacement with basic R259 is expected to affect NAT1 function contrary to the predictions of
SIFT and POLYPHEN-2. The variant E264K was one of the variants with contradictory results from the
predictions. The residue E264 is conserved among the human NATs, M. tuberculosis and M. bovis. The
other sequences have either D or N residues at position 264. This implies that the position accepts acidic
polar residues and hence substituting basic polar K264 would affect the function of NAT1 as predicted
by the SIFT algorithm.
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3.3 Structural analysis
Variant structures were modelled to determine the solvent accessibility, the Gibbs free energy changes
associated with the substitutions and hydrogen bonding or salt bridges associated with the 22 nsSNP
residues. The modelling was carried out with MODELLER, Gibbs from energy calculated with FOLDX
and the hydrogen bonds determined with CHIMERA.
3.3.1 Homology modelling of NAT1
The native structure of NAT1 has eight α-helices, 16 β -strands and 26 loop regions. We were able to
successfully reproduce the native structure of NAT1 with all the eight α-helices, 16 β -strands and 26 loop
regions for all the 22 nsSNP substitutions. Structural superimposition of the variant structures with the
wild-type did not produce visible structural distortions. The variant structures with associated molpdf,
DOPE and GA341 scores are listed in Table 3.3. Near identical profiles were observed between the
DOPE plots of the variant and the wild-type structures (Figures 3.3 and 3.4) and suggests that the models
reflect the wild-type structure. A general trend can be seen across all plots; variant structures around
residues 140 to 215 where most of the nsSNPs are located, show slight variation in energy compared
with the wild-type.
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Table 3.3 DOPE score and molpdf values of variant structures
SNP Status SNP Filename molpdf DOPE Score GA341 Score
Published R64W R64W.pdb 1535.23 -37601.86 1.0
R117T R117T.pdb 1612.84 -37319.45 1.0
V149I V149I.pdb 1539.37 -37511.91 1.0
R166T R166T.pdb 1562.57 -37509.80 1.0
E167Q E167Q.pdb 1567.06 -37261.23 1.0
R187Q R187Q.pdb 1651.64 -37469.41 1.0
M205V M205V.pdb 1667.50 -37590.77 1.0
S214A S214A.pdb 1529.88 -37305.33 1.0
D251V D251V.pdb 1569.23 -37482.27 1.0
E261K E261K.pdb 1546.98 -37559.84 1.0
I263V I263V.pdb 1608.11 -37254.16 1.0
Novel T193S T193S.pdb 1555.35 -37389.62 1.0
F202V F202V.pdb 1564.16 -37272.33 1.0
Q210P Q210P.pdb 1588.94 -37355.79 1.0
D229H D229H.pdb 1607.88 -37341.77 1.0
V231G V231G.pdb 1648.96 -37022.09 1.0
V235A V235A.pdb 1569.63 -37132.11 1.0
T240S T240S.pdb 1602.17 -37333.45 1.0
R242M R242M.pdb 1656.57 -37513.19 1.0
N245I N245I.pdb 1680.36 -37460.92 1.0
S259R S259R.pdb 1612.42 -37350.60 1.0
E264K E264K.pdb 1556.21 -37364.08 1.0
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Figure 3.3 DOPE plots for published NAT1 variants
Plots of the energy profiles of the variant structures along with the energy profiles of the wild-type structure for published
nsSNPs. Each variant energy profile overlaps with the wild-type energy profile. However slight deviations are observed from
residues 40 to 50 and from 140 to 270. Each variant is represented by a different colour.
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Figure 3.4 DOPE plots for novel NAT1 variants
Plots of the energy profiles of the variant structures along with the energy profiles of the wild-type structure for published
nsSNPs. Each variant energy profile overlaps with the wild-type energy profile. However slight deviations are observed from
residues 40 to 50 and from 140 to 270. Each variant is represented by a different colour.
3.3.2 PROCHECK evaluation
Modelled structures have many sources of errors including changes in main chain dihedral angles i.e.
stereochemical errors. The stereochemical qualities of all variant and wild-type structures were assessed
with the PROCHECK suite of programs. All the variant structures of NAT1 (published and novel nsSNPs)
had over 90% of the residues in the most favoured region and none in the disallowed regions of the
Ramachandran plots (Table 3.4). This is an indication that most of the models are of high quality. The
residues in the most favoured region range from 91.6-93.5%.
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Table 3.4 Ramachandran plot results for NAT1 variants
SNP Status SNP variant MFR(R)1 MFR(%) AAR (R)2 AAR (%) GAR(R)3 GAR(%) DR(%)4
Published Wild-type 243 93.1 15 5.7 3 1.1 0.0
R64W 241 92.3 16 6.1 4 1.1 0.0
R117T 242 92.7 15 5.7 4 1.1 0.0
V149I 243 93.1 15 5.7 3 1.1 0.0
R166T 243 93.1 15 5.7 3 1.1 0.0
E167Q 243 93.1 14 5.4 4 1.5 0.0
R187Q 242 92.7 16 6.1 3 1.1 0.0
M205V 241 92.3 18 6.7 2 0.8 0.0
S214A 243 93.1 15 5.7 3 1.1 0.0
D251V 241 92.3 17 6.5 3 1.1 0.0
E261K 242 92.7 16 6.1 3 1.1 0.0
Novel I263V 242 92.7 16 6.1 3 1.1 0.0
T193S 242 92.7 16 6.1 3 1.0 0.0
F202V 242 92.7 15 5.7 4 1.5 0.0
Q210P 242 93.1 16 6.2 2 0.8 0.0
D229H 239 91.6 19 7.3 3 1.1 0.0
V231G 240 92.0 18 6.9 3 1.1 0.0
V235A 241 92.3 17 6.5 3 1.1 0.0
T240S 241 92.7 16 6.2 3 1.2 0.0
R242M 240 92.0 18 6.9 3 1.1 0.0
N245I 244 93.5 14 5.4 3 1.1 0.0
S259R 241 92.3 18 6.9 2 0.8 0.0
E264K 239 91.6 20 7.7 2 0.8 0.0
1MFR(R) - Most Favoured Region (Residues), 2AAR (R) - Additionally Allowed Region (Residues), 3GAR (R)- Generously
Allowed Region (Residues), 4DR- Disallowed Region.
The variant structure containing the nsSNP E167Q has the least residues while E264K has the greatest
residues occurring in the additionally allowed region. No residues were observed in the disallowed
regions for any of the variant structures.
3.3.3 Solvent accessibility
The accessibility of donor and acceptor atoms to water molecules affect residue interactions. The rel-
ative solvent accessibilities of the side chains of the amino acids for residue interactions are therefore
vital when considering effects of amino acid substitutions. We used NACCESS to calculate the solvent
accessible surface areas of the nsSNP residues (Table 3.5). For most variants we observed only minor
changes in solvent accessibilities. However, the published nsSNP I263V and novel nsSNPs D229H,
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V235G, S259R and E264K (novel) had in excess of 10% change in relative solvent accessibility.
Table 3.5 Relative solvent accessibilities of NAT1 variants
Published Novel
SNP Variant (WR1) /% (VR2)/% SNP Variant (WR) /% (VR)/%
R64W 13.4 8.60 T193S 23.9 22.3
R117T 41.0 45.00 F202V 0.1 3.3
V149I 39.0 34.30 Q210P 12.6 13.4
R166T 22.60 25.30 D229H 67.3 83.3
E167Q 65.0 64.20 V231G 0.7 21.3
R187Q 4.0 4.90 V235A 0.0 0.1
M205V 19.2 15.00 T240S 3.6 3.9
S214A 72.2 72.00 R242M 3.4 5.7
D251V 2.1 1.10 N245I 66.5 67.6
E261K 87.5 88.7 S259R 47.3 80.3
I263V 6.2 18.00 E264K 92.8 78.8
1WR - Wild-type residue, 2VR - Variant residue.
The most significant change in solvent accessibility was variant S259R (47.3% to 80.3%) and the lowest
change was V235A variant ( 0.0% to 0.1%).
3.3.4 Protein structure stability
The Gibbs free energy change associated with a mutation is a measure of the stability of the protein.
A greater than zero Gibbs free energy change is indicative of instability while a negative value implies
a stable variant protein structure [93]. The effects of the 22 nsSNPs on NAT1 structure stability was
calculated with FOLDX. Stability analysis for NAT1 published nsSNPs indicated that 5 published and 5
novel nsSNPs have Gibbs free energy values greater than zero (Table 3.1).
The negative Gibbs free energy changes associated with published variants R117T, V149I, R187Q,
M205V, E261K, I263V and novel variants F202V, Q210P, N245I, T193S, R242M, E264K suggests the
structures are relatively stable compared to the wild-type. This means that the above variants should have
no stability effects on human NAT1 function. For the above published nsSNPs, all except R187Q were
confirmed by both SIFT and POLYPHEN-2 algorithms to have no effects on NAT1 function. Variant
R187Q was confirmed by SIFT to have no effect while POLYPHEN-2 indicated that it will affect the
function of NAT1. Among the novel nsSNPs with negative Gibbs free energy changes, only T193S was
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confirmed by both algorithms to have no functional effects. Variants F202V and Q210P had contrarily
predicted functional effects from both algorithms to the Gibbs free energy changes. While the prediction
of variant R242M by SIFT confirmed the Gibbs free energy change, POLYPHEN-2 result was in the
contrary.
The positive Gibbs free energy associated with the variants R64W, R166T, E167Q, S214A, D251V (pub-
lished) and D229H, V231G, V235A, T240S, S259R (novel) indicate destabilizing effects to the variant
structures. Thus the above variants are expected to affect the function of NAT1. For the published nsS-
NPs R64W, R166T and D251V, the predictions by both algorithms were in agreement with the Gibbs
free energy changes. However, predictions of the functional effects of variants E167Q and S214A con-
tradicted the Gibbs free energy changes. For the novel nsSNPs with positive Gibbs free energy changes,
D229H, V231G, V235A were confirmed by both algorithms to have functional effects on NAT1 while
T240S and S259R showed contrary results from the Gibbs free energy changes.
However, there is no single threshold in Gibbs free energy change at which we are certain that changes in
function have occurred. Bromberg and Burkhard [97] attribute the above to the following three reasons;
firstly, the threshold at which a mutation is destabilizing enough to disrupt function by reducing the
number of folded active proteins depends on the unfolding energy of the wild-type molecule, which
ranges from 3-15 kcal/mol [102]. This indicates that more stable proteins require a larger change to
significantly alter the concentration of active molecules. Secondly, without exactly knowing the particular
mechanism of protein function, protein destabilization or stabilization events are equally likely to alter
function. Finally, destabilizations affecting active sites of the protein may not be manifest in a large
∆G, but can still affect function. Bromberg and Burkhard [97] conducted a study to find the threshold
energy value that would cause change in function and found that 16 of 19 (84%) stabilizing mutants
(∆G < 0 kcal/mol; average = -0.73) were functionally disruptive. Similarly, 36 of 45 (80%) destabilizing
mutants (∆G = 1.67) affected function. This implies the direction of stability change alone could not
determine functional effect. They [97] demonstrated that in general magnitudes of both destabilizing and
stabilizing changes are not very informative. Bromberg and Burkhard [97] concluded that the knowledge
of stability is not adequate enough to predict functional effects and that many substitutions that change
protein function have no effect on stability.
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The variants F202V, Q210P and N245I had stability changes of -1.49, -6.20 and -4.80 kcal/mol respec-
tively i.e. stabilizing but were predicted by both SIFT and POLYPHEN-2 to affect NAT1 function.
Similarly T240S and S259R had destabilizing Gibbs free energy changes of 2.47 and 3.50 kcal/mol
respectively, yet were predicted as having no effect on function of NAT1. This is similar to the obser-
vation by Bromberg and Burkhard [97] that the direction of stability change alone could not determine
functional effect. On the other hand D229H, V231G and V235A had destabilizing Gibbs free energy
changes (8.33, 6.29, 6.98 kcal/mol respectively) and were predicted to have functional alterations on
NAT1. Also T193S had a stabilizing energy change (-8.92 kcal/mol) and predicted by both algorithms as
functionally neutral as observed by Bromberg and Burkhard [97]. The nsSNPs R242M and E264K had
-7.79 kcal/mol and -15 kcal/mol respectively but both had contradictory results from the two algorithms.
While R242M variant was predicted to be neutral by the SIFT algorithm in agreement with the Gibbs
free energy change, POLYPHEN-2 predicted it as possibly damaging. Also E264K nsSNP was predicted
by SIFT to affect NAT1 function in disagreement with the Gibbs free energy change value but predicted
as neutral by POLYPHEN-2. Thus no clear correlation could be seen from the Gibbs free energy changes
and functional effects predicted by the two algorithms. Comparing the predictive abilities of both al-
gorithms with each other and/or with the Gibbs free energy changes, SIFT and POLYPHEN-2 perform
better than Gibbs free energy changes in discriminating neutral and non-neutral nsSNPs as observed by
Bromberg and Burkhard [97].
From the above analysis of the 22 nsSNPs no correlation can be observed between predicted functional
effects and the Gibbs free energy (stability) changes calculated.
3.3.5 Residue interaction determination (hydrogen bonds and salt bridges)
The substitution of one amino acid for another can lead to a loss or gain of residue interactions in proteins.
A significant loss of such interactions due to a nsSNP substitution can affect the structure and function
of the protein. We used UCSF CHIMERA to calculate the hydrogen bonds or salt bridges for each of the
22 nsSNP residues (Figures 3.5-3.18, Tables 3.1 and 3.2). The eight published nsSNPs that have been
structurally analysed by Walraven and colleagues using structural analysis [83] are shown in Appendices
B-I. Our analysis of these 8 nsSNPs indicated similar results. However, 3 additional nsSNPs (R117T,
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R166T and E167Q) were not analysed by Walraven and colleagues and were included in this study. Four
out of 14 nsSNPs analysed showed different results compared to predictions by SIFT and POLYPHEN-2.
Analysis of the remaining 10 were in agreement with the predictions of SIFT and POLYPHEN-2. The
11 novel and the three published nsSNPs are discussed below.
G1165T (R242M) variant
Structural analysis showed that R242 is situated on β14 with its side-chain oriented towards the core of
the protein. The main-chain of R242 forms hydrogen bonds with residue V231 (V231 N: R242 O, 2.9
Å and R242 N: V231 O, 2.9 Å) (Figure 3.5 left panel). The side-chain of R242 forms salt bridges with
Q168 (R242 NH1: Q168 OE1, 3.3 Å; R242 NE2: Q168 OE1, 2.9 Å) and D251 (R242 NH1: D251 OD2,
3.2 Å).
Figure 3.5 Residue interactions involving wild-type residue R242 and SNP residue M242
Wild-type residue R242 forms three side-chain salt bridges with D251 and Q168. It also forms two main-chain H-bonds with
V231. Substitution of SNP residue M242 results in loss of the three side-chain H-bonds. Blue denotes nitrogen-atoms, yellow
represents sulphur, red represents oxygen-atoms, grey represents main-chains and cyan represents H-bonds.
The residues R242 and D251 are on the anti-parallel β14 and β15 strands respectively of domain III while
Q168 is situated on β10. The interaction with D251 is not necessary for the stability of the β -strands
but provides an additional stability to the loop-stabilizing interaction between D251 and the domain II
loop residue Q168 [103]. This and other interactions between the domain II loop and the domain III
47
 
 
 
 
β -strands contribute to the protein stability [104]. Replacing the R residue with M residue would result
in loss of the side-chain hydrogen bond interactions of R242 except the main-chain hydrogen bonds with
basic V231 (V231 N: M242 O, 3.0 Å and M242 N: V231 O, 2.8 Å) (Figure 3.5, right panel). This is
expected to affect the dynamics and conformation of the domain II loop, thereby altering NAT1 protein
stability and function. This variant is therefore expected to affect NAT1 protein function in agreement
with POLYPHEN-2 prediction.
A1174T (N245I) variant
The residue N245 is situated on β14 and its main-chain forms a hydrogen bond with D251 which is
situated on β15 (N245 N: D251 OD1, 2.9 Å) and both are in domain III (Figure 3.6, left panel). This
interaction is not necessary for the stability of the β -strands [83]. Replacement of polar N residue for
hydrophobic I residue maintains this interaction (I245 N: D251 OD1, 2.9 Å) (Figure 3.6, right panel).
Hydrophobic interactions are not possible because neighbouring residues are far more than 4.0 Å apart.
However placing a hydrophobic residue into a hydrophilic environment will destabilize the protein. Thus
the variant N245I is expected to alter the stability of NAT1 as predicted by SIFT and POLYPHEN-2.
Figure 3.6 Residue interactions involving wild-type residue N245 and SNP residue I245
A single H-bond formed between wild-type residue N245 and D251 is maintained by the SNP residue I245. Blue denotes
nitrogen-atoms, red represents oxygen-atoms, grey represents main-chains and cyan represents H-bonds.
48
 
 
 
 
T1217G (S259R) variant
The residue S259 is the first residue on α10 of domain III. Its side-chain forms hydrogen bonds with the
side-chains of E261 (S259 OG.A: E261 OE1, 2.7 Å and S259 OG.B: E261 OE1, 3.5 Å) and also with
E262 (S259 N: E262 OE1, 2.9 Å) (Figure 3.7, left panel). The main-chain of S259 also forms hydrogen
bonds with E262 (E262 N: S259 O, 3.1 Å and S259 OG.B: E262 OE1, 2.9 Å). These hydrogen bonds
are expected to stabilize α10 of domain III. Substitution of the S residue with R residue results in the
loss of the side-chain hydrogen bonds except the main-chain hydrogen bonds with E262 (R259 N: E262
OE1, 2.9 Å and E262 N: R259 O, 3.1 Å) (Figure 3.7, right panel). This loss of hydrogen bonds would
destabilize the α10 of domain III and is reflected in the positive Gibbs free energy change accompanying
the substitution (Table 3.2). The replacement of R is expected to contribute to hydrophobic interactions
from its side-chain. However, its side-chain is directed away from near-by residues and such interactions
may not be possible. The instability due to loss of hydrogen bonds would affect the function of the S259R
variant protein. This is in stark contrast to the predictions of SIFT and POLYPHEN-2.
Figure 3.7 Residue interactions involving wild-type residue S259 and SNP residue R259
Side-chain of wild-type residue S259 forms three salt bridges with E262 and E261 while its main-chain forms one salt bridge
and one H-bond with E261 and E262 respectively. Substitution of SNP residue R259 results in the loss of the side-chain salt
bridges of S259. Blue denotes nitrogen-atoms, red represents oxygen-atoms, grey represents main-chains and cyan represents
H-bonds.
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G1230A (E264K) variant
The residue E264 is located on α10 of the NAT1 crystal structure. The main-chain of E264 forms a
hydrogen bond with residue K268 on α10 (K268 N: E264 O, 3.2 Å) (Figure 3.8, left panel). This
hydrogen bond should stabilize the regular secondary structure α10. Substitution with residue K results
in the hydrogen bond, K268 N: K264 O, 3.2 Å (Figure 3.8, right panel). Since the substitution maintains
the interaction between 264 and 268 residues, no structural changes are expected from this substitution.
This variant is therefore not expected to have altered function in agreement with POLYPHEN-2 but
different from the SIFT prediction.
Figure 3.8 Residue interactions involving wild-type residue E264 and SNP residue K264
The single main-chain H-bond between wild-type residue E264 and K268 is maintained by SNP residue K264. Blue denotes
nitrogen-atoms, red represents oxygen-atoms, grey represents main-chains and cyan represents H-bonds.
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G350C (R117T) variant
The crystal structure of human NAT1 shows two hydrogen bonds between R117 and I114 i.e. (I114 N:
R117 O, 2.9 Å) and/or (R117 N: I114 O, 3.0 Å) (Figure 3.9 left panel) [56] which are maintained with
the replacement of T i.e. (I114 N: T117 O, 2.9 Å) and/or (T117 N: I114 O, 2. 8 Å) (Figure 3.9 right
panel). Replacing R which favours α-helix formation with T which favours β -strand formation [69, 105]
in β5 should stabilise the β secondary structure. The variant R117T has been reported to be a variant of
human NAT1 [106] but experimental functional analysis of this variant has not been reported. However,
from the structural analysis this substitution is not expected to have any significant effect on the structure
and hence function of NAT1 as indicated by both SIFT and POLYPHEN-2.
Figure 3.9 Residue interactions involving wild-type residue R117 and SNP residue T117
The main-chain of wild-type residue R117 forms two H-bonds with I114 which are maintained by T117. Red represents
oxygen-atoms, grey represents main-chains and cyan represents H-bonds.
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G497C (R166T) variant
In the crystal structure of NAT1, R166 is located on the connection between β9 and β10 and forms a
salt bridge with D251 (R166 NH1: D251 OD1, 3.0 Å) and two hydrogen bonds with V146 (R166 NH1:
V146 O, 3.1 Å and R166 NH2: V146 O, 2.6 Å) in domain II (Figure 3.10 left panel). These bonds should
contribute to the stability of the domain loop formed by β9 and β10 strands. However, a replacement
with T results in only one bond (T166 OG1: N249 O, 2.6 Å) on β15 in domain III (Figure 3.10 right
panel). This loss in hydrogen bonds and the salt bridge due to the substitution is expected to affect the
stability of the domain II loop and that of domain III loop. This would subsequently affect the protein
structure leading to a functional impairment as predicted. The acetylation status (rapid, intermediate or
slow) of this variant has not been reported. From the structural analysis the substitution could affect the
structure and is expected to affect the function of the NAT1 protein as revealed by SIFT and POLYPHEN-
2 predictions.
Figure 3.10 Residue interactions involving wild-type residue R166 and SNP residue T166
The side-chain of wild-type residue R166 forms a salt bridge with main-chain of D251 and two H-bonds with V146. Sub-
stitution of SNP residue T166 results in a loss of the three bonds with new H-bond between T166 and N249 (hidden). Blue
denotes nitrogen-atoms, red represents oxygen-atoms, grey represents main-chains and cyan represents H-bonds.
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G498C (E167Q) variant
The residue E167 occurs in β10 and forms a hydrogen bond with D251 on β15 in domain II (D251 N:
E167 O, 2.7 Å) (Figure 3.11 left panel). This bond is expected to maintain the stability of the four anti-
parallel β -strands. Replacement with Q maintains the hydrogen bond with D251: (D251 N: Q167 O, 2.7
Å) (Figure 3.11 right panel). The variant structure did not show any observable change in the secondary
structures or orientation of the four anti-parallel β -strands. Thus no change in the function of the NAT1
protein is expected and this is in agreement with SIFT and POLYPHEN-2 predictions.
Figure 3.11 Residue interactions involving wild-type residue E167 and SNP residue Q167
Wild-type residue E167, forms a single H-bond with D251 which is maintained by the replacement of SNP residue Q167.
Blue denotes nitrogen-atoms, red represents oxygen-atoms, grey represents main-chains and cyan represents H-bonds.
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A1017T (T193S) variant
Oxygen atom (OG1) of T193 which is in the inter-domain region interacts with K195 also in the inter-
domain region through the following hydrogen bond: (K195 N: T193 OG1, 3.4 Å) (Figure 3.12 left
panel) and in addition forms two hydrogen bonds with solvent molecules. These interactions should
contribute to the stability of the inter-domain region. However, the conservative substitution of polar T
for polar S results in the following interaction (R197 NH1: S193 OG, 3.1 Å) (Figure 3.12 right panel).
The side-chain of residue R197 forms a hydrogen bond with solvent but upon the substitution of T193
with S193 forms the above hydrogen bond instead. Thus the stability of the inter-domain region is
expected to remain constant. Thus the integrity of the region is maintained and hence no significant
effect to the structure of the NAT1 protein is expected. These results support the predictions of SIFT and
POLYPHEN-2 algorithms.
Figure 3.12 Residue interactions involving wild-type residue T193 and SNP residue S193
The side-chain of wild-type residue T193 forms a H-bond with main-chain of K195. Substitution of S193 leads to a side-
chain to side-chain H-bond with residue R197. Blue denotes nitrogen-atoms, red represents oxygen-atoms, grey represents
main-chains and cyan represents H-bonds.
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T1046G (F202V) variant
The crystal structure of NAT1, shows that residue F202 is located on α8 with its side-chain oriented
towards the core of the protein structure while its main-chain forms a hydrogen bond with I199 in the
inter-domain region (F202 N: I199 O, 2.9 Å) and N206 in domain III (N206 N: F202 O, 2.8 Å)(Figure
3.13 left panel), both of which are in α8 together with the CoA binding residue Y208 (Figure 1.4). Such
interactions are maintained by the replacement of F with V (V202 N: I199 O, 2.8 Å and N206 N: V202
O, 2.8 Å) (Figure 3.13 right panel).
Figure 3.13 Residue interactions involving wild-type residue F202 and SNP residue V202
The wild-type residue F202 forms two main-chain H-bonds with N206 and I199. These main-chain H-bonds are maintained
when replaced with SNP residue F202V. The conservative substitution of hydrophobic F with V maintain the hydrophobic
interactions within the protein core. However, replacing F with a high propensity for α-helix formation and therefore stabilises
α8 with V which favours β -strand formation instead [69, 107] resulted in a change in the orientation of the side-chain of
N206 and that could affect the orientation of the CoA binding residue Y208 and hence the conformation of the co-factor
binding pocket. Blue denotes nitrogen-atoms, red represents oxygen-atoms, grey represents main-chains and cyan represents
H-bonds.
Moreover, the conservative substitution of hydrophobic F with V should maintain the hydrophobic in-
teractions within the protein core. However, replacing F with a larger size and stabilises α8 with V of
smaller size [69, 107] resulted in a change in the orientation of the side-chain of N206 and that could af-
fect the orientation of the CoA binding residue Y208 and hence the conformation of the co-factor binding
pocket. This would thus affect the substrate binding and lead to a change in function of NAT1 protein.
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Hence this variant is likely to cause a change in the function of NAT1 protein as predicted by SIFT and
POLYPHEN-2 analysis.
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A1069C (Q210P) variant
In the crystal structure of NAT1, Q210 is located on α8 and its side-chain interacts with residue M48
in domain I (M48 N: Q210 OE1, 2.8 Å and Q210 NE2: M48 O, 2.9 Å) and residue T207 in domain
III (Q210 N: T207 O, 3.3 Å) which is also in α8 (Figure 3.14 left panel). The Q210 residue main-
chain also interacts with N206 in domain III, α8 (Q210 NE2: N206 O, 3.0 Å). These interactions should
maintain the structural integrity of both domains and the orientation of the CoA binding residue Y208 as
well as stabilizing the 5-residue connection between α3 and α4. A non-conservative substitution of the
polar Q210 residue which favours α-helix formation with a hydrophobic cyclic P210 which has a high
tendency to form bends or turns [69, 107] results in a complete loss of these interactions (Figure 3.14
right panel). This subsequently would affect the stability of both domains, the connection between α3
and α4 and the orientation of the critical residue Y208. This substitution would significantly affect the
structure of NAT1 protein and hence its function is expected to be altered as predicted by both SIFT and
POLYPHEN-2 algorithms.
Figure 3.14 Residue interactions involving wild-type residue Q210 and SNP residue P210
Wild-type residue Q210 forms one main-chain H-bond with T207 and three side-chain H-bonds, one with N206 and two with
M48. All theses are lost substituting SNP residue P210. Blue denotes nitrogen-atoms, yellow denotes sulphur, red represents
oxygen-atoms, grey represents main-chains and cyan represents H-bonds.
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G1125C (D229H) variant
The residue D229 is situated on a loop/turn between anti-parallel β12 and β13 strands. D229 forms two
hydrogen bonds with residue T227 (D229 N: T227 OG1, 3.3 Å and T227 OG1: D229 OD1, 3.5 Å) on
β12 strand in domain III (Figure 3.15 left panel). It also interacts with residue F244 (F244 N: D229
O, 2.9 Å) on β14 strand in domain III as well as a solvent molecule. These hydrogen bonds should
contribute to the stability of the loop or turn between β12 and β13 and stability of the four anti-parallel
β -strands of domain III. The substitution of an acidic residue D229 with the basic residue H229 results
in a loss of these interactions except for F224 (F244 N: H229 O, 3.0 Å) (Figure 3.15, right panel). The
loss of these interactions would affect the stability of the loop or turn between β12 and β13 and stability
of the four anti-parallel β -strands of domain III. This variant may thus alter the function of NAT1 protein
as predicted by the SIFT and POLYPHEN-2 predictions.
Figure 3.15 Residue interactions involving wild-type residue D229 and SNP residue H229
D229 forms two H-bonds with T227 and one H-bond with F244. Substituting H229 leads to lost of two bonds except the
main-chain H-bond with F244. Blue denotes nitrogen-atoms, red represents oxygen-atoms, grey represents main-chains and
cyan represents H-bonds.
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T1132G (V231G) variant
The residue V231 is located on β13, the second β -strand of four anti-parallel β -strands and interacts
with R242 on β14, both of which are on domain III (V231 N: R242 O, 2.9 Å and R242 N: V231 O, 2.9
Å) (Figure 3.16 left panel). These hydrogen bonds should stabilize the β -sheet. Such interactions are
maintained with the conservative substitution of G (G231 N: R242 O, 3.0 Å and R242 N: G231 O, 2.8
Å) (Figure 3.16 right panel) with an additional hydrogen bond with solvent. The side-chain of V231 is
0.70% exposed and oriented to the hydrophobic core and the substituted G231 is 21.30% exposed to the
hydrophobic core (Table 3.5). This increase in solvent accessible area following the substitution makes
the side-chain of R242 more accessible to water and could cause instability in the hydrophobic core, as
indicated by the Gibbs free energy change and affect the four anti-parallel β -strands. This can potentially
affect the orientation of the CoA residue Y208. This variant is thus expected to affect the function of
NAT1 protein as predicted by the algorithms.
Figure 3.16 Residue interactions involving wild-type residue V231 and SNP residue G231
Wild-type residue V231 forms two main-chain H-bonds with R242 which are maintained in the SNP residue G231. Blue
denotes nitrogen-atoms, red represents oxygen-atoms, grey represents main-chains and cyan represents H-bonds.
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T1144C (V235A) variant
The structural analysis indicated that residue V235 located at the end of β13, interacts with T238 in
domain III (V235 N: T238 O, 2.9 Å and T238 N: V235 O, 2.9 Å) (Figure 3.17 left panel) and creates
a hydrogen bond with surrounding solvent molecule. Replacement with A residue maintains the bonds
with T238 (A235 N: T238 O, 2.8 Å and T238 N: A235 O, 2.8 Å) (Figure 3.17 right panel). The side-chain
of V235 is 0.00% exposed (Table 3.5) and oriented to the hydrophobic core contributing to hydrophobic
interactions in the core of the protein with close residues L180 and I290. Possible CH..pi-interaction
with H283 may contribute to stabilization of the protein core. Substituted A231 is 0.10% exposed to the
hydrophobic core (Table 3.5). This increment in solvent accessible area following the substitution could
cause instability in the hydrophobic core by hydrogen bonding with water and affect the orientation of the
four anti-parallel β -strands and subsequently affect the CoA residue Y208. This may potentially impact
negatively on NAT1 protein function as predicted by both algorithms.
Figure 3.17 Residue interactions involving wild-type residue V235 and SNP residue A235
Wild-type residue V235 forms two main-chain H-bonds with T238 which are maintained by SNP residue A235. Blue denotes
nitrogen-atoms, red represents oxygen-atoms, grey represents main-chains and cyan represents H-bonds.
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C1159G (T240S) variant
The structural analysis of residue T240 showed that it is located on β14 with its side-chain oriented
towards the core of the protein. It forms three hydrogen bonds with residue C233 (C233 N: T240 O, 3.0
Å; T240 N: C233 O, 2.8 Å and T240 OG1: C233 O, 2.8 Å) (Figure 3.18 left panel). Both residues are
in domain III but T240 is on β14 while C233 is on β13. These bonds should stabilise the anti-parallel
strands β12, β13, β14 and β15 in the domain III. The conservative substitution of the polar residue T
for polar S maintains such interactions with residue C233 (C233 N: S240 O, 3.0 Å; S240 N: C233 O, 2.8
Å and S240 OG: C233 O, 3.0 Å) (Figure 3.18 right panel). As such the stability of the four anti-parallel
β -strands is expected to remain roughly the same. This suggests that the substitution should not have
any significant effect on the structure of NAT1 protein and its function as indicated by the predictions of
SIFT and POLYPHEN-2.
Figure 3.18 Residue interactions involving wild-type residue T240 and SNP residue S240
Wild-type residue T240 forms two main-chain H-bonds with C233 and one side-chain H-bond with C233. These are main-
tained in SNP residue S240. Blue denotes nitrogen-atoms, red represents oxygen-atoms, yellow represents sulphur, grey
represents main-chains and cyan represents H-bonds.
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Biological interpretation of the molecular phenotype in relation to a disease phenotype is a complex
matter [108]. It is also difficult to assess how tolerant a specific protein is to structural alteration. Addi-
tionally, the natural rigidity of a protein may cause the change in stability that is allowed before severe
conformational changes are introduced and on the cellular level biological interpretation is even harder:
because it is difficult to predict the role the protein quality control system plays in this tolerance level
noting that not all interactions are described at the molecular level [108]. Reumers et al. [108], indicated
that even if we can predict the molecular effect accurately, this might not necessarily result in a disease
phenotype because of functional redundancy of the protein. However, the residue interaction analyses
above, have confirmed the functional effects predicted by SIFT and POLYPHEN-2 for the published vari-
ants R117T, R166T, E167Q and novel variants T193S, F202V, Q210P, D229H, V231G, V235A, T240S
and R242M representing 71% (10/14) of all variants analysed. Analysis of variants N245I and S259R in-
dicated contradictory results to the predictions of the algorithms. Analysis of variants R242M and E264K
(with contradictory SIFT and POLPHEN-2 results) gave results that agreed with the POLYPHEN-2 re-
sults.
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Chapter 4
CONCLUSION
The effects of nsSNPs on the structure and function of proteins are routinely analyzed using SIFT and
POLYPHEN-2 prediction algorithms. The false-negative rate of these two algorithms results in as much
as 25% of nsSNPs without any evidence of putative impact on protein function. The underlying algorithm
implemented in SIFT and POLYPHEN-2 use a combination of sequence features and limited structural
information. In the absence of experimental evidence for functional consequences of nsSNPs and the
limited accuracy of SIFT and POLYPHEN-2, this study aimed to explore the use of homology modeling
including residue interactions, Gibbs free energy changes and solvent accessibility as additional evidence
for predicting nsSNP function. An ability to pin-point functionally important nsSNPs in the context of
NAT1, an enzyme that metabolizes tuberculosis drugs, will add value to treatment decisions.
This study analyzed 11 nsSNPs previously identified in NAT1 in Caucasians and more recently in a South
African mixed ancestry population. However, 8 of these SNPs were recently subjected to structural-
functional analysis and provided an internal control for our study methodology. An additional 11 nsSNPs
were found specifically in the same South African population group. The structural analysis implemented
in this study showed contradictory results for the functions of two nsSNPs compared to the predictions
made by SIFT and POLYPHEN-2. The structural analysis also provided additional evidence for two
nsSNPs that were in agreement with only one of the two algorithms (POLYPHEN-2). The functions of
the remaining 10 nsSNPs were consistent with those predicted by SIFT and POLYPHEN-2.
This study provided the first evaluation of the functional effects of 11 newly characterized nsSNPs on the
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NAT1 tuberculosis drug-metabolizing enzyme. The six functionally important nsSNPs will be tested ex-
perimentally by creating a SNP construct that will be cloned into an expression vector. These combined
computational and experimental studies will advance our understanding of NAT1 structure-function rela-
tionships and allow us to interpret the NAT1 genetic polymorphisms in individuals who are slow or fast
acetylators.
The results, albeit a small dataset demonstrate that the routinely used algorithms are not without flaws and
that improvements in functional prediction of nsSNPs can be obtained by close scrutiny of the molecular
interactions of wild type and variant amino acids.
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Appendix A
Command line options
A.1 UCSF CHIMERA
By clicking the “Favorites” option in CHIMERA, “Command Line” option was then selected. In the
command line, each residue was selected by “select: # of residue” and the side-chains shown from the
“Actions” option by selecting “Atoms/Bonds”, then “Show”. The H-bonding of the wild-type residues
in the wild-type structure (2PQT of NAT1) and the variants residues in the modeled structures were
calculated with the “FindHBond” function by choosing “Structure analysis” from “Tools”. In the “H-
bond Parameters” dialog box, “Relax H-bonds constraints” was by 0.4Å and 20.0 degrees. Only find
H-bonds with at least one end selected and write information to reply log, were checked. From the reply
log file, residues that form H-bonds with the residue of interest were also selected and shown. This then
indicated the hydrogen bonding of the residue with its surrounding residues. The best orientations of the
images were saved.
A.2 FOLDX
The “RepairPDB” command was used to repair all residues (the wild-type and of each variant pdb struc-
ture) with bad torsion angles, or Vander Waals’ clashes, or total energy at a temperature of 298°C, pH
of 7, ionic strength of 0.05 and Van der Waals radius of 2. The above parameters were contained in the
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“run.txt” file together with the “RepairPDB” command with “list.txt” containing the PDB file of each
variant or wild-type structure. This was run from the command line by typing “foldx”, then selecting “3”
and typing “run.txt”. The new PDB structure files obtained were then added to the list2.txt file. The free
energy changes were then calculated with the “Stability” command with the above conditions/options.
A.3 NACCESS
The NACCESS program was installed locally and used. The program was run from the linux terminal
with “naccess variant/wild-type PDBCode.pdb”. This produced a PDBCode.log, PDBCode.rsa and PDB-
Code.asa files containing the run information, relative accessibilities and absolute solvent accessibilities
respectively of the atoms and residues in each structure.
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Appendix B
Residue interactions of wild-type residue R64 and SNP residue W64. . . . . . . . . . . . . . . . .
R64 W64
Left panel- wild-type; Right panel- variant. Seven hydrogen bonds with the wild-type results in two bonds substituting
tryptophan for arginine.
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Appendix C
Residue interactions of wild-type residue V149 and SNP residue I149 . . . . . . . . . . . . . . . .
Left panel- wild-type; Right panel- variant. Additional bond formed following isoleucine substitution.
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Appendix D
Residue interactions of wild-type residue R187 and SNP residue Q187 . . . . . . . . . . . . . . .
Left panel- wild-type; Right panel- variant. Main-chain bonds maintained with substituted glutamine
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Appendix E
Residue interactions of wild-type residue I263 and SNP residue V263 . . . . . . . . . . . . . . . .
Left panel- wild-type; Right panel- variant. No change in hydrogen bonds
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Appendix F
Residue interactions of wild-type residue M205 and SNP residue V205. . . . . . . . . . . . . . .
Left panel- wild-type; Right panel- variant. No change in hydrogen bonds
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Appendix G
Residue interactions of wild-type residue S214 and SNP residue A214. . . . . . . . . . . . . . . .
Left panel- wild-type; Right panel- variant. Additional bond formed between alanine 214 and arginine 256
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Appendix H
Residue interactions of wild-type residue D251 and SNP residue V251. . . . . . . . . . . . . . . .
Left panel- wild-type; Right panel- variant. A significant number of hydrogen bonds are lost following substitution of valine.
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Appendix I
Residue interactions of wild-type residue E261 and SNP residue K261. . . . . . . . . . . . . . . .
Left panel- wild-type; Right panel- variant. Loss of side-chain bonds with S259 replacing lysine for glutamic acid.
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